A form of ketamine delivered as a nasal spray is showing effectiveness in treating severe depression. The FDA has approved esketamine for adults with treatment-resistant depression; the patient self-administers it in a supervised clinical setting.
Dr. Caleb Battersby, director of interventional psychiatry at UConn Health, joins the UConn Health Pulse podcast to explain how it works and why it’s providing hope for patients who haven’t had success with other treatments.
It can translate into people being able to kind of make lifestyle changes probably more quickly and more effectively than they do with oral medications. — Dr. Caleb Battersby
